SINOVAC's quadrivalent influenza vaccine collaborated with a local partner has been approved by the Directorate General of Drug Administration (DGDA) in Bangladesh for marketing use recently. This is the first authorization that SINOVAC acquired from overseas for its Quadrivalent Influenza vaccine following its approval in China in June 2020. The first batch of semi-finished products has arrived in Bangladesh to support local influenza prevention.
Bangladesh is a tropical country in the Northern Hemisphere, and its annual seasonal influenza epidemic occurs typically during the monsoon period, from May to September, and the annual peak is June to July each year according to the observation during 2010-2019. The disease burden of influenza is moderately high in Bangladesh, with an estimated annual incidence of 458 cases per 100,000 people and 6 to 11 influenza-associated deaths per 100,000 people across all age groups.
Over the years, SINOVAC has continued helping Bangladesh defend against infectious diseases. SINOVAC's trivalent influenza vaccine and inactivated hepatitis A vaccine were respectively approved in 2015 and 2017 in Bangladesh. After the outbreak of COVID-19, SINOVAC's inactivated COVID-19 vaccine, CoronaVac®, was approved for emergency use in Bangladesh in June 2021. Up to now, the total supply of CoronaVac® in Bangladesh has exceeded 60 million doses and played an important role in preventing the spread of COVID-19 in Bangladesh.
Sinovac Biotech Ltd., (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases.
SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A and B, seasonal influenza, pneumococcal disease, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), varicella, mumps, and poliomyelitis.
The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The Healive®, hepatitis A vaccine, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) was prequalified by the WHO.
SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program.
SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations.
For more information, please see the Company’s website at www.sinovac.com.
Sinovac Biotech Ltd.